Jeffrey Sklar
Founder at Sklar Kirsh LLP
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Andrew T. Kirsh | M | - |
Sklar Kirsh LLP
Sklar Kirsh LLP Miscellaneous Commercial ServicesCommercial Services Sklar Kirsh LLP provides legal services. The private company is based in Los Angeles, CA. The company was founded by Andrew T. Kirsh, Jeffrey Sklar. | 11 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Steven C. Berger | M | 63 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | 1 years |
Richard Rosenblum | M | 65 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | 1 years |
Mike M. Goldberg | M | 65 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | - |
Kenneth D. Pearsen | M | 63 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | - |
Joseph M. Leone | M | 70 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | - |
Nachum Stein | M | 75 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | - |
Dave Stefansky | M | 52 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | 1 years |
Joseph Sierchio | M | 74 |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | 3 years |
Laura Rivers-Bowerman | F | - |
HepaLife Technologies, Inc.
HepaLife Technologies, Inc. Medical/Nursing ServicesHealth Services Alliqua, Inc. is a biomedical products company focused on the development and manufacturing of proprietary technologies in the fields of drug delivery, advanced wound care and liver health preservation. It intends to develop active ingredient and transdermal drug delivery products, primarily utilizing the proprietary hydrogel technology platform manufactured by its subsidiary AquaMed Technologies, Inc. The firm develops HepaMate, an extracorporeal cell-based bioartificial liver system designed to combine blood detoxification with liver cell therapy to provide whole liver function in patients with the most severe forms of liver failure. Its HepaMate is comprised of a blood plasma separation cartridge, a hollow-fiber bioreactor filled with proprietary porcine liver cells, a charcoal column, an oxygenator, circuit tubing and a plasma reservoir. The company was founded on October 21, 1997 and is headquartered in New York, NY. It changed its name from HepaLife Technologies, Inc. in January 2011. | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 10 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jeffrey Sklar
- Personal Network